These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 9294477

  • 1. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J.
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [Abstract] [Full Text] [Related]

  • 2. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
    Muss HB, Case LD, Atkins JN, Bearden JD, Cooper MR, Cruz JM, Jackson DV, O'Rourke MA, Pavy MD, Powell BL.
    J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
    [Abstract] [Full Text] [Related]

  • 3. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
    Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD.
    J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
    [Abstract] [Full Text] [Related]

  • 4. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
    Beltrán M, Alonso MC, Ojeda MB, Izquierdo A, Ferrer J, Picó C, Anglada L, Catalán G, Batiste-Alentorn E, Tusquets I.
    Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
    [Abstract] [Full Text] [Related]

  • 5. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
    Sonoo H, Senoo T, Nishiki M, Morimoto T, Takashima S.
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
    [Abstract] [Full Text] [Related]

  • 6. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN.
    J Clin Oncol; 2011 Oct 10; 29(29):3869-76. PubMed ID: 21911723
    [Abstract] [Full Text] [Related]

  • 7. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H, Willemse PH, Tjabbes T, Schweitzer MJ, Sleijfer DT.
    Cancer; 1986 Jul 01; 58(1):7-13. PubMed ID: 2939943
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2011 Dec 15; 17(24):7828-34. PubMed ID: 21998336
    [Abstract] [Full Text] [Related]

  • 9. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
    Rose C, Kamby C, Mouridsen HT, Andersson M, Bastholt L, Møller KA, Andersen J, Munkholm P, Dombernowsky P, Christensen IJ.
    Breast Cancer Res Treat; 2000 May 15; 61(2):103-10. PubMed ID: 10942095
    [Abstract] [Full Text] [Related]

  • 10. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.
    Wils JA, Bliss JM, Marty M, Coombes G, Fontaine C, Morvan F, Olmos T, Pérez-López FR, Vassilopoulos P, Woods E, Coombes RC.
    J Clin Oncol; 1999 Jul 15; 17(7):1988-98. PubMed ID: 10561249
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer.
    Mouridsen HT, Palshof T, Rose C.
    Recent Results Cancer Res; 1980 Jul 15; 71():169-77. PubMed ID: 6988913
    [Abstract] [Full Text] [Related]

  • 12. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
    Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N, National Surgical Adjuvant Breast and Bowel Project.
    J Clin Oncol; 2002 Oct 15; 20(20):4141-9. PubMed ID: 12377957
    [Abstract] [Full Text] [Related]

  • 13. Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.
    Noguchi S, Yamamoto H, Inaji H, Imaoka S, Koyama H.
    Jpn J Cancer Res; 1989 Mar 15; 80(3):244-8. PubMed ID: 2524460
    [Abstract] [Full Text] [Related]

  • 14. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.
    Kloke O, Klaassen U, Oberhoff C, Hartwich G, Szanto J, Wolf E, Heckmann M, Huhn R, Stephan L, Schnepper U, Donsbach GM, Bechtel C, Rudolph R, Berke A, Borquez D, Hawig I, Hirche H, Schindler AE, Seeber S, Becher R.
    Breast Cancer Res Treat; 1999 May 15; 55(1):51-9. PubMed ID: 10472779
    [Abstract] [Full Text] [Related]

  • 15. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study.
    De Lena M, Tommasi S, Schittulli F, Lorusso V, Paradiso A.
    Tumori; 1990 Apr 30; 76(2):190-5. PubMed ID: 2139523
    [Abstract] [Full Text] [Related]

  • 16. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A.
    Breast Cancer Res Treat; 2004 Jun 30; 85(3):247-54. PubMed ID: 15111763
    [Abstract] [Full Text] [Related]

  • 17. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
    Nemoto T, Patel JK, Rosner D, Dao TL, Halvorson H.
    J Surg Oncol; 1989 Aug 30; 41(4):226-9. PubMed ID: 2526907
    [Abstract] [Full Text] [Related]

  • 18. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.
    Cancer Res; 2000 Apr 15; 60(8):2155-62. PubMed ID: 10786679
    [Abstract] [Full Text] [Related]

  • 19. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
    Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Børmer O, Høst H.
    Breast Cancer Res Treat; 1990 Nov 15; 17(1):45-50. PubMed ID: 2151369
    [Abstract] [Full Text] [Related]

  • 20. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
    Pyrhönen S, Ellmén J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes DF.
    Breast Cancer Res Treat; 1999 Jul 15; 56(2):133-43. PubMed ID: 10573106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.